Key Findings
The North America kidney cancer therapeutics and diagnostics market is predicted to project a CAGR of 5.59% during the forecast period, 2019-2028. The growing number of kidney cancer cases and the collective efforts of the organizations are set to influence the market growth in the region.

Market Insights
The North America kidney cancer therapeutics and diagnostics market growth analysis entails the assessment of Canada and the United States. Canada encompasses an increasing number of kidney cases and several non-profit organizations. The Canadian Cancer Society estimates that almost 7,500 will be diagnosed with kidney and renal pelvis cancer in 2020, along with 1,950 deaths. Kidney cancer is among the top ten most common cancer in Canadians, as per the Kidney Cancer Research Network of Canada (KCRNC). The market players in the country are getting approvals for combination therapy products. Merck announced the approval of its anti-PD-1 therapy, KEYTRUDA, combined with Inlyta (axitinib), by Health Canada. It is considered as a significant advancement in the treatment of kidney cancer. It will aid in extending survival outcomes for patients with advanced renal cell carcinoma. Such factors are projected to drive the market growth of Canada.

Competitive Insights
Some of the eminent companies in the market include, Bayer AG, Becton, Dickinson and Company (BD), Bristol-Myers Squibb Company, Exelixis, Amgen Inc, etc.
Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments